Figure 4
Combination of sorafenib and YC-1 inhibited growth of HepG2 tumor xenografts. HepG2 cells were injected subcutaneously into the upper right flank region of nude mice. When the tumor reached a mean size 100 mm3, mice were treated with combination of sorafenib (30 mg/kg/day) and YC-1 (10 mg/kg/day) or either drug alone every day for up to the 24th day. A, Tumor size was measured with a caliper rule every 3 days. Data were presented as the mean tumor volumes of mice in both treatment and vehicle groups on the days post-treatment. B, Average tumor weight was shown at the end of the experiments. C and D, Tumor sections were stained for PCNA, PAPR, p-STAT3, cyclin D1 and survivin. Representive images of the immunohistochemistry assay were shown (200×). E, Tumor sections were stained for CD31 and VEGF. Representive images of the immunohistochemistry assay were shown (200×). Error bars represent the SEM of tumor weight. P value <0.05 was considered statistically significant; ***p < 0.001, **p < 0.01, *p < 0.05.